Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials

AIM: Bevacizumab and ramucirumab are antiangiogenic monoclonal antibodies, which target vascular endothelial growth factor-A and vascular endothelial growth factor receptor-2, respectively, used in various cancers. Bleeding events have been described with these two agents. We conducted an up-to-date...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Bingkun, Wang, Weilan, Zhang, Dezhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110629/
https://www.ncbi.nlm.nih.gov/pubmed/30174444
http://dx.doi.org/10.2147/OTT.S166151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110629/
https://www.ncbi.nlm.nih.gov/pubmed/30174444
http://dx.doi.org/10.2147/OTT.S166151

Ejemplares similares